


This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims**

1. (Original) A compound of the formula (I)



wherein,

R1 is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  
R2 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, NRaRb or  
polyfluoroalkyl having 1, 2, 3 or 4 carbon atoms,  
Ra and Rb  
are independently of each other hydrogen, linear or branched alkyl having 1, 2, 3, 4, 5 or 6  
carbon atoms or Ra and Rb form, together with the nitrogen atom to which they are  
attached, a 5- or 6-membered heterocycle, which may optionally contain another hetero  
atom chosen from O, S and N,  
R3 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4,  
5 or 6 carbon atoms or hydroxyl,  
R4 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4,  
5 or 6 carbon atoms or hydroxyl,  
R5 is hydrogen or halogen,  
Ar is a 9- or a 10-membered bicyclic heteroaryl having one, two or three nitrogen atoms,  
which may be linked via any of its positions,  
or a racemic mixture, enantiomer, diastereomer, or tautomer of such compound, or a mixture  
thereof, or a pharmaceutically acceptable salt of such compound, racemic mixture, enantiomer,  
diastereomer, tautomer, or mixture.

2. (Original) A compound according to claim 1, wherein

R1 is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  
R2 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, NRaRb or  
polyfluoroalkyl having 1, 2, 3 or 4 carbon atoms,

Ra and Rb

are independently of each other hydrogen, linear or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or Ra and Rb form, together with the nitrogen atom to which they are attached, a 5- or 6-membered heterocycle, which may optionally contain another hetero atom chosen from O, S and N,

R3 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or hydroxyl,

R4 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or hydroxyl,

R5 is hydrogen or halogen,

Ar is quinoline, isoquinoline, cinnoline or 7H-pyrrolo-[2,3-d]-pyrimidine, which may be linked via any of its positions.

3. (Original) A compound according to claim 1 wherein

R1 is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R2 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, NRaRb or polyfluoroalkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Ra and Rb

are independently of each other hydrogen, linear or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or Ra and Rb form, together with the nitrogen atom to which they are attached, a 5- or 6-membered heterocycle, which may optionally contain another hetero atom chosen from O, S and N,

R3 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or hydroxyl,

R4 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or hydroxyl,

R5 is hydrogen or halogen,

Ar is quinoline, which may be linked via any of its positions.

4. (Original) A compound according to claim 1 wherein

R1 is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R2 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, NRaRb or polyfluoroalkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

## Ra and Rb

are independently of each other hydrogen, linear or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or Ra and Rb form, together with the nitrogen atom to which they are attached, a 5- or 6-membered heterocycle, which may optionally contain another hetero atom chosen from O, S and N,

R3 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or hydroxyl,

R4 is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or hydroxyl,

R5 is hydrogen or halogen,

Ar is isoquinoline, which may be linked via any of its positions.

5. (Original) A compound according to claim 1 which is:

3-guanidinocarbonyl-1-(isoquinol-1-yl)-1H-indole,

3-guanidinocarbonyl-1-(quinol-4-yl)-1H-indole,

3-guanidinocarbonyl-1-(quinol-2-yl)-1H-indole,

3-guanidinocarbonyl-1-(isoquinol-1-yl)-5-methyl-1H-indole,

3-guanidinocarbonyl-5-methyl-1-(quinol-2-yl)-1H-indole;

3-guanidinocarbonyl-5-methyl-1-(quinol-4-yl)-1H-indole;

3-guanidinocarbonyl-1-(quinol-3-yl)-1H-indole,

3-guanidinocarbonyl-1-(quinol-6-yl)-1H-indole,

3-guanidinocarbonyl-1-(quinol-8-yl)-1H-indole,

3-guanidinocarbonyl-1-(isoquinol-3-yl)-1H-indole,

3-guanidinocarbonyl-6-methoxy-1-(quinol-4-yl)-1H-indole,

3-guanidinocarbonyl-6-hydroxy-1-(quinol-4-yl)-1H-indole,

6-fluoro-3-guanidinocarbonyl-1-(quinol-4-yl)-1H-indole,

5-fluoro-3-guanidinocarbonyl-1-(quinol-4-yl)-1H-indole,

4-chloro-3-guanidinocarbonyl-1-(quinol-4-yl)-1H-indole,

5-chloro-3-guanidinocarbonyl-1-(quinol-4-yl)-1H-indole,

6-chloro-3-guanidinocarbonyl-1-(quinol-4-yl)-1H-indole,

4-fluoro-3-guanidinocarbonyl-1-(quinol-4-yl)-1H-indole,

3-guanidinocarbonyl-4-methyl-1-(quinol-4-yl)-1H-indole,

3-guanidinocarbonyl-4-trifluoromethyl-1-(quinol-4-yl)-1H-indole,  
4-dimethylamino-3-guanidinocarbonyl-1-(quinol-4-yl)-1H-indole,  
3-guanidinocarbonyl-1-(cinnolin-4-yl)-1H-indole, or  
5-methoxy-3-guanidinocarbonyl-1-(cinnolin-4-yl)-1H-indole,  
or a tautomer thereof or a pharmaceutically acceptable salt of such compound or tautomer.

6. (Original) A pharmaceutical composition for human, veterinary, or phytoprotective use comprising an effective amount of a compound according to claim 1 together with a pharmaceutically acceptable medium.

7. (Canceled).

8. (Currently Amended) A method for the treatment or prophylaxis of cardiovascular disease, metabolic disease, cancerous disease, or fibrotic disease comprising administering to a patient in need thereof, an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said patient.

9. (Currently Amended) A method for the treatment or prophylaxis of acute or chronic damage to, or disorders or indirect sequelae of organs and tissues caused by ischemic or reperfusion events;  
arrhythmias, life-threatening cardiac ventricular fibrillation, myocardial infarction, angina pectoris;  
ischemic states of the heart, ischemic states of the peripheral and central nervous system, stroke, cerebral oedema attack, ischemic states of peripheral organs and tissues;  
states of shock;  
diseases in which cellular proliferation represents a primary or secondary cause; cancer, metastasis, prostate hypertrophy, prostate hyperplasia;  
atherosclerosis, disturbances of lipid metabolism, high blood pressure;  
disorders of the central nervous system;  
non-insulin-dependent diabetes mellitus, late damage from diabetes;  
thromboses, disorders resulting from endothelial dysfunction, intermittent claudication;

fibrotic disorders of internal organs, fibrotic disorders of the liver, fibrotic disorders of the kidney, fibrotic disorders of vessels, fibrotic disorders of lung, fibrotic disorders of the heart;

heart failure, congestive heart failure, acute or chronic inflammatory disorders, disorders caused by protozoa;

malaria, or coccidiosis in poultry, comprising administering to a patient in need thereof, an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter ( $\text{Na}^+/\text{H}^+$ -exchanger) activity of said patient.

10. (Currently Amended) A method according to claim 9 for the treatment ~~or prophylaxis~~ of allergic shock, cardiogenic shock, hypovolaemic shock or bacterial shock.

11. (Currently Amended) A method according to claim 9 for the treatment ~~or prophylaxis~~ of essential hypertension.

12. (Currently Amended) A method according to claim 9 for the treatment ~~or prophylaxis~~ of disorders resulting from overexcitability of the CNS.

13. (Currently Amended) A method according to claim 12, for the treatment ~~or prophylaxis~~ of epilepsy or centrally induced convulsions.

14. (Currently Amended) A method according to claim 9 for the treatment ~~or prophylaxis~~ of anxiety states, depressions or psychoses.

15. (Previously Presented) A method for protecting an organ in a transplant donor during organ transplantation, both before and during the removal of the organ, comprising administering to said donor, an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter ( $\text{Na}^+/\text{H}^+$ -exchanger) activity of said donor.

16. (Previously Presented) A method for protecting a removed organ during treatment with, or storage in physiological bath liquids, comprising contacting said organ with a compound according to claim 1 to inhibit the cellular sodium-proton antiporter ( $\text{Na}^+/\text{H}^+$ -exchanger) activity of said organ.

17. (Previously Presented) A method for protecting a removed organ during transfer to a recipient organism during organ transplantation, comprising contacting said organ with a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said organ.

18. (Previously Presented) A method for preventing age-related tissue change, in a patient in need thereof, comprising administering to said patient, an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said patient.

19. (Previously Presented) A method for prolonging life in a patient in need thereof, comprising administering to said patient, an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said patient.

20. (Previously Presented) A method for the treatment or reduction of the cardiotoxic effects in thyrotoxicosis in a patient in need thereof, comprising administering to said patient an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said patient.

21 - 35. (Canceled).

36. (Currently Amended) A method for the treatment or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs or tissues caused by ischemic or reperfusion events in a patient in need thereof, comprising administering to said patient an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said patient.

37. (Canceled).

38. (Currently Amended) A method for the treatment of life-threatening cardiac ventricular fibrillation, in a patient in need thereof, comprising administering to said patient, an

effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said patient.

39. (Canceled).

40. (Currently Amended) A method for the treatment or prophylaxis of metastasis in a patient in need thereof, comprising administering to said patient an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said patient.

41. (Canceled)

42. (Currently Amended) A method for the treatment or prophylaxis of fibrotic disorders of the heart, heart failure, or congestive heart failure, in a patient in need thereof, comprising administering to said patient an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said patient.

43. (Canceled)

44. (Currently Amended) A method for the treatment or prophylaxis of a disease which is related to NHE, in a patient in need thereof, comprising administering to said patient an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said patient.


45. (Canceled)

46. (Currently Amended) A method for the treatment or prophylaxis of a disease which is related to NHE1, in a patient in need thereof, comprising administering to said patient an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said patient.

47. (Canceled)

48. (Previously Presented) A method for protecting the organs or blood vessels during surgical intervention, in a patient in need thereof, comprising administering to such patient an effective amount of a compound according to claim 1 to inhibit the cellular sodium-proton antiporter (Na<sup>+</sup>/H<sup>+</sup>-exchanger) activity of said patient.

49. (Original) A process for the preparation of a compound according to claim 1 characterised in that



- a) a heteroaryl halide  $\text{ArX}$  of the formula (VI) is reacted with a 3-alkoxycarbonyl-1H-indole of the formula (II)
- b) the obtained 3-alkoxycarbonyl-1-heteroaryl-indole of the formula (III) is saponified
- c) the 3-carboxy-1-heteroaryl-indole of the formula (IV) is converted in the acid chloride of formula (V)
- d) the obtained product of formula (V) is reacted with guanidine, the product is isolated and is optionally converted into a pharmaceutically acceptable salt, wherein in the compounds of the formula II, III, IV, V and VI

Ar, R1, R2, R3, R4 and R5 are defined as in claim 1,

X is F, Cl, Br or I and

R is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.

50. (Currently Amended) A method for the treatment or prophylaxis of cardiovascular disease, metabolic disease, cancerous disease, or fibrotic disease comprising administering to a patient in need thereof, an effective amount of a compound according to claim 1.

51. (Currently Amended) A method for the treatment or prophylaxis of acute or chronic damage to, or disorders or indirect sequelae of organs and tissues caused by ischemic or reperfusion events; arrhythmias, life-threatening cardiac ventricular fibrillation, myocardial infarction, angina pectoris; ischemic states of the heart, ischemic states of the peripheral and central nervous system, stroke, cerebral oedema attack, ischemic states of peripheral organs and tissues; states of shock; diseases in which cellular proliferation represents a primary or secondary cause; cancer, metastasis, prostate hypertrophy, prostate hyperplasia; atherosclerosis, disturbances of lipid metabolism, high blood pressure; disorders of the central nervous system; non-insulin-dependent diabetes mellitus, late damage from diabetes; thromboses, disorders resulting from endothelial dysfunction, intermittent claudication; fibrotic disorders of internal organs, fibrotic disorders of the liver, fibrotic disorders of the kidney, fibrotic disorders of vessels, fibrotic disorders of lung, fibrotic disorders of the heart; heart failure, congestive heart failure, acute or chronic inflammatory disorders, disorders caused by protozoa; malaria, or coccidiosis in poultry, comprising administering to a patient in need thereof, an effective amount of a compound according to claim 1.

52. (Original) A method for protecting an organ in a transplant donor during organ transplantation, both before and during the removal of the organ, comprising administering to said donor, an effective amount of a compound according to claim 1.

53. (Original) A method for protecting a removed organ during treatment with, or storage in physiological bath liquids, comprising contacting said organ with a compound according to claim 1.

54. (Original) A method for protecting a removed organ during transfer to a recipient organism during organ transplantation, comprising contacting said organ with a compound according to claim 1.

55. (Original) A method for preventing age-related tissue change, in a patient in need thereof, comprising administering to said patient, an effective amount of a compound according to claim 1.

56. (Original) A method for prolonging life in a patient in need thereof, comprising administering to said patient, an effective amount of a compound according to claim 1.

57. (Original) A method for the treatment or reduction of the cardiotoxic effects in thyrotoxicosis in a patient in need thereof, comprising administering to said patient an effective amount of a compound according to claim 1.

58. (Currently Amended) A method for the treatment or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs or tissues caused by ischemic or reperfusion events in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.

59. (Original) A method for the treatment of life-threatening cardiac ventricular fibrillation, in a patient in need thereof, comprising administering to said patient, a pharmaceutically effective amount of a compound according to claim 1.

60. (Currently Amended) A method for the treatment or prophylaxis of metastasis in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.

61. (Currently Amended) A method for the treatment or prophylaxis of fibrotic disorders of the heart, heart failure, or congestive heart failure, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.

62. (Currently Amended) A method for the treatment or prophylaxis of a disease which is related to NHE, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.

63. (Currently Amended) A method for the treatment or prophylaxis of a disease which is related to NHE1, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.

64. (Original) A method for protecting the organs or blood vessels during surgical intervention, in a patient in need thereof, comprising administering to such patient a pharmaceutically effective amount of a compound according to claim 1.